TY  - JOUR
AU  - Trewin-Nybråten, Cassia B
AU  - Leithe, Sigrid
AU  - Paulsen, Torbjørn
AU  - Langseth, Hilde
AU  - Fortner, Renée Turzanski
TI  - Ovarian cancer survival by residual disease following cytoreductive surgery: a nationwide study in Norway.
JO  - British journal of cancer
VL  - 132
IS  - 12
SN  - 0007-0920
CY  - Edinburgh
PB  - Nature Publ. Group
M1  - DKFZ-2025-00874
SP  - 1158-1166
PY  - 2025
N1  - #LA:C020# / 2025 Jun;132(12):1158-1166
AB  - Residual disease (RD) following cytoreductive surgery is prognostic for epithelial ovarian cancer (EOC) patients. Few studies have evaluated RD and survival by tumor histotype and across continuous RD diameter.2608 individuals with stages III-IV invasive EOC diagnosed between 2013 and 2022 were identified using the Cancer Registry of Norway. In flexible parametric models, we compared excess mortality comparing RD versus no macroscopic residual disease (NMRD); systemic anti-cancer therapy was evaluated in a sub-cohort from 2019. Excess mortality was assessed across continuous RD size using restricted cubic splines.Among 1849 patients with cytoreductive surgery, survival was worse for individuals with RD (vs. NMRD), excess hazard ratio (EHR) = 2.62 (95
LB  - PUB:(DE-HGF)16
C6  - pmid:40287590
DO  - DOI:10.1038/s41416-025-03018-0
UR  - https://inrepo02.dkfz.de/record/300694
ER  -